Approval

Approval  ·  Weekly Digest 23 August to 29 August 2025
DATROWAY approved in China for patients with previously treated metastatic HR Positive, HER2 negative breast cancer

Weekly Digest – August 2025 Weekly Digest – August 2025 25 August 2025: DATROWAY approved in China for patients with previously treated metastatic HR Positive, HER2 negative breast cancer DATROWAY (Datopotamab deruxtecan) has been approved in China for patients with […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 23 August to 29 August 2025
ENHERTU approved in Japan as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following at least one endocrine therapy

Weekly Digest – August 2025 Weekly Digest – August 2025 25 August 2025: ENHERTU approved in Japan as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following at least one endocrine therapy ENHERTU […]

by Sandhya Ramalingam

Continue Reading